Seeking Alpha

Rosetta Genomics (ROSG -3.6%) slips after Sidoti cut the shares to Neutral earlier today. The...

Rosetta Genomics (ROSG -3.6%) slips after Sidoti cut the shares to Neutral earlier today. The stock has essentially been dead money since last November, trading in a narrow range between $4 - $5 after cratering off a $23 higher earlier in the year. Just yesterday, Aegis cut its price target on the stock as well. On the surface, that may not seem too significant, but it's worth noting that Aegis has acted as the placement agent for the last four of ROSG’s public offerings.
From other sites
Comments (1)
  • jsIRA
    , contributor
    Comments (2695) | Send Message
     
    ROSG price is heavily manipulated. Aegis made huge money after as the placement agency brought the stock almost 1,000% higher. Now they already made enough money on this stock and it is time for them to downgrade it. Follow the big money as this company never sell its product. Revenue near zero.
    13 Apr 2013, 02:30 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector